AAN 2016

Most patients on first-line anti-epileptic drug (AED) monotherapy continue initial treatment for nearly 1.5 years, according to a retrospective database study reported at the 68th AAN Annual Meeting.

The advantages of fingolimod over injectable disease-modifying therapies (iDMTs) in patient retention and treatment satisfaction support use of fingolimod in early relapsing-remitting multiple sclerosis (MS) in the real world.

Treatment of acute migraine with AVP-825, an investigational Breath-Powered Bi-Directional intranasal delivery system containing sumatriptan powder 22mg, resulted in higher rates of total migraine freedom.

IncobotulinumtoxinA injections customized by site and dose improved hand and forearm tremor symptoms patients with Parkinson’s disease without increasing hand weakness

Levodopa-carbidopa intestinal gel is safe and effective in Japanese, Taiwanese, and Korean patients with advanced Parkinson’s disease

Durlaza, an extended-release aspirin formulation, provides “sustained antiplatelet effects over 24 hours” in patients with type 2 diabetes mellitus (T2DM).

For both smokers and nonsmokers, adding clopidogrel to aspirin therapy is associated with a reduced risk of second stroke in the 90 days following a stroke or high-risk transient ischemic attack (TIA)—but that association is much stronger among smokers

Data from patients with relapsing-remitting multiple sclerosis (MS) who received the humanized monoclonal antibody daclizumab high-yield process (HYP) “extend previous observations” on the agent’s rapid pharmacodynamic effects on CD56bright natural killer (NK) cells and regulatory T-cells (Tregs) at treatment initiation, providing additional evidence for an immunomodulatory effect.

Parkinson’s disease (PD) “off”-period symptoms control is better following administration of an inhaled levodopa powder formulation (CVT-301) than placebo.

Dietary sodium intake is not associated with MS risk in a prospective cohort of women from the Nurses’ Health Study and Nurses’ Health Study II